Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 10/2016

01-07-2016 | AdisInsight Report

Pimavanserin: First Global Approval

Author: Anthony Markham

Published in: Drugs | Issue 10/2016

Login to get access

Abstract

Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson’s disease psychosis. Up to 60 % of patients with Parkinson’s disease may develop Parkinson’s disease psychosis, which is associated with increased morbidity and mortality and has few treatment options. This article summarizes the milestones in the development of pimavanserin leading to this first approval for the treatment of hallucinations and delusions in patients with Parkinson’s disease psychosis.
Literature
1.
Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001.CrossRefPubMed
2.
3.
Acadia Pharmaceuticals Inc. ACADIA Pharmaceuticals enters agreement with Biovail to conclude collaboration and regain North American rights to pimavanserin [media release]. 28 Oct 2010. http://​www.​acadia-pharm.​com.
4.
Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2- methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist. J Pharmacol Exp Ther. 2006;317(2):910–8.CrossRefPubMed
5.
Vanover KE, Robbins-Weilert D, Wilbraham DG, et al. Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. J Clin Pharmacol. 2007;47(6):704–14.CrossRefPubMed
6.
Vanover KE, Robbins-Weilert D, Wilbraham DG, et al. The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers. J Clin Pharmacol. 2007;47(7):915–9.CrossRefPubMed
7.
Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. [Erratum appears in Lancet. 2014 Jul 5;384(9937):28]. Lancet. 2014;383(9916):533–40.CrossRefPubMed
8.
Mills R, Friedman JH, Ondo W, et al. Efficacy and tolerability of pimavanserin in PD psychosis: analysis of an integrated phase 3 placebo-controlled dataset [abstract no. 156]. Mov Disord. 2015;30(Suppl 1):S60.
9.
Mills R, Isaacson S, Azulay JP, et al. Long-term effectiveness of Nuplazid™ (pimavanserin) in PD psychosis: data from 2 open-label studies [abstract no. P 2.056]. Parkinsonism Relat Disord. 2016;22(Suppl 2):e92–3.
10.
Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin 2A receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35:881–92.CrossRefPubMed
11.
Meltzer HY, Elkis H, Vanover K, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: comparison with reference dose risperidone, 6 mg/day. Schizophr Res. 2012;141(2–3):144–52.CrossRefPubMed
12.
Metadata
Title
Pimavanserin: First Global Approval
Author
Anthony Markham
Publication date
01-07-2016
Publisher
Springer International Publishing
Published in
Drugs / Issue 10/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0597-9

Other articles of this Issue 10/2016

Drugs 10/2016 Go to the issue

Adis Drug Evaluation

Secukinumab: A Review in Ankylosing Spondylitis

Adis Drug Evaluation

Sugammadex: A Review of Neuromuscular Blockade Reversal

Review Article

Fimasartan: A New Angiotensin Receptor Blocker

Leading Article

Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions

Current Opinion

Pain Relief for Acute Urolithiasis: The Case for Non-Steroidal Anti-Inflammatory Drugs

Adis Drug Evaluation

Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome